{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T04:59:15Z","timestamp":1787979555315,"version":"build-2784847793"},"reference-count":43,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2002,3,1]],"date-time":"2002-03-01T00:00:00Z","timestamp":1014940800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2002,3,1]],"date-time":"2002-03-01T00:00:00Z","timestamp":1014940800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Blood Cells, Molecules, and Diseases"],"published-print":{"date-parts":[[2002,3]]},"DOI":"10.1006\/bcmd.2002.0510","type":"journal-article","created":{"date-parts":[[2002,9,16]],"date-time":"2002-09-16T10:51:07Z","timestamp":1032173467000},"page":"196-208","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":156,"title":["Deferiprone versus Deferoxamine in Patients with Thalassemia Major: A Randomized Clinical Trial"],"prefix":"10.1006","volume":"28","author":[{"given":"Aurelio","family":"Maggio","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gennaro","family":"D'Amico","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Morabito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcello","family":"Capra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Calogero","family":"Ciaccio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Cianciulli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felicia","family":"Di Gregorio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Garozzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Malizia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmelo","family":"Magnano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonino","family":"Mangiagli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Quarta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Rizzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Domenico Giuseppe","family":"D'Ascola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aroldo","family":"Rizzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"Midiri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1006\/bcmd.2002.0510_RF1","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1056\/NEJM199409013310903","article-title":"Survival in medically treated patients with homozygous \u03b2-thalassemia","volume":"331","author":"Olivieri","year":"1994","journal-title":"N. Engl. J. Med."},{"key":"10.1006\/bcmd.2002.0510_RF2","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1182\/blood.V76.3.435.435","article-title":"Treatment of Cooley's anemia","volume":"76","author":"Fosburg","year":"1990","journal-title":"Blood"},{"key":"10.1006\/bcmd.2002.0510_RF3","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1056\/NEJM198604033141402","article-title":"Visual and auditory neurotoxicity in patients receiving subcutaneous deferoxamine infusions","volume":"314","author":"Olivieri","year":"1986","journal-title":"N. Engl. J. Med."},{"key":"10.1006\/bcmd.2002.0510_RF4","first-page":"153","article-title":"Ocular and auditory toxicity of high dose subcutaneous deferoxamine therapy","volume":"20","author":"Orton","year":"1985","journal-title":"Can. J. Ophthalmol."},{"key":"10.1006\/bcmd.2002.0510_RF5","first-page":"287","article-title":"Acute aphasia and loss of vision with desferrioxamine overdose","volume":"9","author":"Dickeroff","year":"1987","journal-title":"Am. J. Pediatr. Hematol. Oncol."},{"key":"10.1006\/bcmd.2002.0510_RF6","first-page":"199a","article-title":"Sensorimotor neurophaty associated with high dose desferrioxamine","volume":"78","author":"Giardina","year":"1993","journal-title":"Blood"},{"key":"10.1006\/bcmd.2002.0510_RF7","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1111\/j.1365-2265.1995.tb02684.x","article-title":"Short stature in homozygous \u03b2-thalassaemia is due to disproportionate truncal shortening","volume":"42","author":"Rodda","year":"1995","journal-title":"Clin. Endocrinol."},{"key":"10.1006\/bcmd.2002.0510_RF8","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1111\/j.1600-0609.1988.tb00198.x","article-title":"High-dose desferrioxamine as a cause of growth failure in thalassaemic patients","volume":"40","author":"Piga","year":"1988","journal-title":"Eur. J. Haematol."},{"key":"10.1006\/bcmd.2002.0510_RF9","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1007\/BF01955263","article-title":"Growth and development in thalassaemia major patients with severe bone lesions due to desferrioxamine","volume":"155","author":"De Sanctis","year":"1996","journal-title":"Eur. J. Pediatr."},{"key":"10.1006\/bcmd.2002.0510_RF10","first-page":"371","article-title":"The effects of subcutaneous deferoxamine administration on renal function in thalassemia major","volume":"54","author":"Koren","year":"1992","journal-title":"Int. J. Haematol."},{"key":"10.1006\/bcmd.2002.0510_RF11","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1016\/0140-6736(92)90598-W","article-title":"Pulmonary toxic effects of continuous desferrioxamine administration in acute iron poisoning","volume":"339","author":"Tenenbein","year":"1992","journal-title":"Lancet"},{"key":"10.1006\/bcmd.2002.0510_RF12","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1016\/0140-6736(90)92962-H","article-title":"Comparison of oral iron chelator L1 and desferrioxamine in iron-loaded patients","volume":"336","author":"Olivieri","year":"1990","journal-title":"Lancet"},{"key":"10.1006\/bcmd.2002.0510_RF13","first-page":"496","article-title":"Oral iron chelating therapy. A single center interim report on deferiprone (L1) in thalassemia","volume":"83","author":"Mazza","year":"1998","journal-title":"Haematologica"},{"key":"10.1006\/bcmd.2002.0510_RF14","series-title":"Therapeutic Drug Monitoring","article-title":"An investigation into variability in the therapeutic response to deferiprone in patients with thalassemia major","author":"Diav-Citrin","year":"1999"},{"key":"10.1006\/bcmd.2002.0510_RF15","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1007\/s002770050236","article-title":"Long-term treatment of transfusional iron overload with the oral iron chelator deferiprone (L1): A Dutch multicenter trial","volume":"73","author":"Kersten","year":"1996","journal-title":"Ann. Hematol."},{"key":"10.1006\/bcmd.2002.0510_RF16","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1182\/blood.V80.3.593.593","article-title":"Efficacy and possible adverse effects of the oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one (L1) in thalassemia major","volume":"80","author":"Al-Refaie","year":"1992","journal-title":"Blood"},{"key":"10.1006\/bcmd.2002.0510_RF17","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1056\/NEJM199504063321404","article-title":"Iron-chelation therapy with oral deferiprone in patients with thalassemia major","volume":"332","author":"Olivieri","year":"1995","journal-title":"N. Engl. J. Med."},{"key":"10.1006\/bcmd.2002.0510_RF18","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1111\/j.1365-2141.1995.tb05274.x","article-title":"Results of long-term deferiprone (L1) therapy: A report by the International Study Group on Oral Iron Chelators","volume":"91","author":"Al-Refaie","year":"1995","journal-title":"Br. J. Haematol."},{"key":"10.1006\/bcmd.2002.0510_RF19","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1111\/j.1365-2141.1992.tb06445.x","article-title":"Long-term assessment of efficacy and safety of L1, an oral iron chelator, in transfusion dependent thalassaemeia: Indian trial","volume":"82","author":"Agarwal","year":"1995","journal-title":"Br. J. Haematol."},{"key":"10.1006\/bcmd.2002.0510_RF20","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1111\/j.1365-2141.1990.tb07887.x","article-title":"Long-term trial with the oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one (L1). I. Iron chelation and metabolic studies","volume":"76","author":"Kontoghiorghes","year":"1990","journal-title":"Br. J. Haematol."},{"key":"10.1006\/bcmd.2002.0510_RF21","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1111\/j.1365-2141.1990.tb07888.x","article-title":"Long-term trial with the oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one (L1). H. Clinical observations","volume":"76","author":"Bartlett","year":"1990","journal-title":"Br. J. Haematol."},{"key":"10.1006\/bcmd.2002.0510_RF22","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1182\/blood.V91.1.295","article-title":"Long-term trial of deferiprone in 51 transfusion-dependent iron overloaded patients","volume":"91","author":"Hoffbrand","year":"1998","journal-title":"Blood"},{"key":"10.1006\/bcmd.2002.0510_RF23","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1056\/NEJM199808133390701","article-title":"Long-term safety and effectiveness of iron-chelation therapy with deferiprone for thalassemia major","volume":"339","author":"Olivieri","year":"1998","journal-title":"N. Engl. J. Med."},{"key":"10.1006\/bcmd.2002.0510_RF24","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s002280050584","article-title":"Meta-analytic review of the clinical effectiveness of oral deferiprone (L1)","volume":"55","author":"Addis","year":"1999","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"10.1006\/bcmd.2002.0510_RF25","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1159\/000040962","article-title":"Sequential use of deferiprone and desferrioxamine in primary school children with thalassaemia major in Turkey","volume":"102","author":"Aydinok","year":"1999","journal-title":"Acta Haematol."},{"key":"10.1006\/bcmd.2002.0510_RF26","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1159\/000039759","article-title":"Factors influencing effectiveness of deferiprone in a thalassemia major clinical setting","volume":"104","author":"Del Vecchio","year":"2000","journal-title":"Acta Haematol."},{"key":"10.1006\/bcmd.2002.0510_RF27","series-title":"The Clinical Approach to Thalassemia","author":"Modell","year":"1984"},{"key":"10.1006\/bcmd.2002.0510_RF28","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1182\/blood.V81.1.239.239","article-title":"Rapid and simultaneous typing of hemoglobin S, hemoglobin C and seven Mediterranean \u03b2-thalassemia mutations by covalent reverse dot-blot analysis: Application to prenatal diagnosis in Sicily","volume":"81","author":"Maggio","year":"1993","journal-title":"Blood"},{"key":"10.1006\/bcmd.2002.0510_RF29","doi-asserted-by":"crossref","first-page":"553","DOI":"10.2165\/00003495-199958030-00021","article-title":"Deferiprone: A review of its clinical potential in iron overload in \u03b2-thalassemia major and other transfusion-dependent diseases","volume":"58","author":"Barman Balfour","year":"1999","journal-title":"Drugs"},{"key":"10.1006\/bcmd.2002.0510_RF30","first-page":"60","article-title":"Il fegato nei pazienti affetti da \u03b2-thalassemia major: Determinazione della concentrazione di ferro con risonanza magnetica","volume":"97","author":"Midiri","year":"1999","journal-title":"Radiol. Med."},{"key":"10.1006\/bcmd.2002.0510_RF31","first-page":"398","article-title":"Iron overload in thalassemia: Comparative analysis of magnetic resonance imaging, serum ferritin and iron content of the liver","volume":"80","author":"Mazza","year":"1995","journal-title":"Haematologica"},{"key":"10.1006\/bcmd.2002.0510_RF32","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1007\/BF01356827","article-title":"Hepatic iron overload in thalassemic patients: Proposal and validation of an MRI method of assessment","volume":"26","author":"Bonetti","year":"1996","journal-title":"Pediatr. Radiol."},{"key":"10.1006\/bcmd.2002.0510_RF33","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1148\/radiology.212.1.r99jl35227","article-title":"Hepatic iron concentration: Noninvasive estimation by means of MR imaging techniques","volume":"212","author":"Bonkovsky","year":"1999","journal-title":"Radiology"},{"key":"10.1006\/bcmd.2002.0510_RF34","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1016\/0168-8278(95)80226-6","article-title":"Histological grading and staging of chronic hepatitis","volume":"22","author":"Ishak","year":"1995","journal-title":"J. Hepatol."},{"key":"10.1006\/bcmd.2002.0510_RF35","series-title":"Statistical Methods for Rates and Proportions","author":"Fleiss","year":"1981"},{"key":"10.1006\/bcmd.2002.0510_RF36","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1001\/jama.1997.03540350075038","volume":"277","year":"1997","journal-title":"JAMA"},{"key":"10.1006\/bcmd.2002.0510_RF37","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1111\/j.1365-2141.1984.tb06096.x","article-title":"Depletion of excessive liver iron stores with desferrioxamine","volume":"58","author":"Cohen","year":"1984","journal-title":"Br. J. Haematol."},{"key":"10.1006\/bcmd.2002.0510_RF38","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1136\/jcp.40.11.1353","article-title":"Iron state and hepatic disease in patients with thalassemia major treated with long-term subcutaneous desferrioxamine","volume":"40","author":"Aldouri","year":"1987","journal-title":"J. Clin. Pathol."},{"key":"10.1006\/bcmd.2002.0510_RF39","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1046\/j.1365-2141.1998.00725.x","article-title":"Liver iron and fibrosis during long-term treatment with deferiprone in Swiss thalassemic patients","volume":"101","author":"Tondury","year":"1998","journal-title":"Br. J. Haematol."},{"key":"10.1006\/bcmd.2002.0510_RF40","first-page":"1712","article-title":"Iron chelation with oral deferiprone in patients with thalassemia","volume":"339","author":"Stella","year":"1998","journal-title":"N. Engl. J. Med."},{"key":"10.1006\/bcmd.2002.0510_RF41","first-page":"92","article-title":"No progression of liver fibrosis in thalassemia major during deferiprone or desferrioxamine iron chelation","volume":"15","author":"Piga","year":"1998","journal-title":"Blood"},{"key":"10.1006\/bcmd.2002.0510_RF42","unstructured":"Galanello, R, De Virgilis, S, Agus, A. et al., 1999, Sequential liver fibrosis grading during deferiprone treatment in patients with thalassemia major. 9th International Conference on Iron Chelation in the Treatment of Thalassemia and Other Diseases, March 25\u201328, Hamburg, Germany."},{"key":"10.1006\/bcmd.2002.0510_RF43","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1046\/j.1365-2141.2000.01866.x","article-title":"Safety profile of the oral iron chelator deferiprone: A multicentre study","volume":"108","author":"Cohen","year":"2000","journal-title":"Br. J. Haematol."}],"container-title":["Blood Cells, Molecules, and Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1079979602905103?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1079979602905103?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T12:19:41Z","timestamp":1761049181000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1079979602905103"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2002,3]]},"references-count":43,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2002,3]]}},"alternative-id":["S1079979602905103"],"URL":"https:\/\/doi.org\/10.1006\/bcmd.2002.0510","relation":{},"ISSN":["1079-9796"],"issn-type":[{"value":"1079-9796","type":"print"}],"subject":[],"published":{"date-parts":[[2002,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Deferiprone versus Deferoxamine in Patients with Thalassemia Major: A Randomized Clinical Trial","name":"articletitle","label":"Article Title"},{"value":"Blood Cells, Molecules, and Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1006\/bcmd.2002.0510","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"converted-article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2002 Elsevier Science (USA). All rights reserved.","name":"copyright","label":"Copyright"}]}}